首页药理学
0


对蛋白质药物的胞内传递的PLGA纳米粒制剂

Formulation of PLGA nanoparticles for intracellular delivery of protein drug
课程网址: http://videolectures.net/slonano07_cegnar_fpn/  
主讲教师: Mateja Cegnar
开课单位: 卢布尔雅那大学
开课时间: 2008-01-18
课程语种: 英语
中文简介:
设计和配制先进的药物输送系统(DDS),如纳米级载体,在药物制剂领域提供了一个有吸引力的研究领域。在生物制药的交付方面有望做出巨大贡献,因为人们清楚地认识到,不充分的分娩是延迟其在临床实践中应用的最重要因素。尽管有一些成功的指导方针,但DDS中蛋白质药物的配方需要逐步采用与传统药物不同的策略和方法,因为蛋白质在保留其生物学功能方面是最微妙的。在我们的工作中选择了模型蛋白质药物半胱氨酸蛋白酶抑制剂,具有灭活半胱氨酸蛋白酶的高潜力,所述半胱氨酸蛋白酶参与肿瘤侵袭和转移过程。纳米颗粒用作载体系统,目的是通过保护蛋白质药物免于生物环境中的过早降解和促进其细胞内递送来提高蛋白质药物的生物利用度。通过水包油包水乳液溶剂扩散法将半胱氨酸蛋白酶抑制剂掺入聚(丙交酯 - 共 - 乙交酯)(PLGA)纳米颗粒中。为了保持其生物活性,开发了优化技术,调整纳米颗粒生产过程中的过程的物理和化学参数。载有半胱氨酸蛋白酶抑制剂的NP具有300-350nm直径的大小,并含有1.6%(w / w)的半胱氨酸蛋白酶抑制剂,保留其起始活性的85%。为了跟踪细胞摄取纳米颗粒,胱抑素在其包封入NP之前用荧光染料(Alexa Fluor 488)标记。图像分析显示NPs快速内化到MCF-10A neoT细胞中,因为在用NP处理后检测到荧光斑点。另一方面,标记的游离半胱氨酸蛋白酶抑制剂非常缓慢地内化,表明NP促进其货物进入细胞。由NP递送的半胱氨酸蛋白酶抑制剂也对细胞内靶组织蛋白酶B发挥其抑制活性,表明在整个配制和递送过程中其完整性得以保持。另一方面,当使用特异于细胞内组织蛋白酶B的底物在相同条件下测试时,游离半胱氨酸蛋白酶抑制剂不赋予组织蛋白酶B的蛋白质活性。我们的结果显示蛋白质药物可以以活性形式配制成PLGA NPs,当适当选择NP生产的工艺参数。 NP还能够促进蛋白质药物向细胞内的递送,使其能够在细胞内靶标上活化
课程简介: Design and formulation of advanced drug delivery systems (DDS), such as nanoscale carriers, presents an attractive research area in the field of drug formulation. A vast contribution is expected in delivery of biopharmaceuticals as is clearly recognized that inadequate delivery is the single most important factor delaying their application in clinical practise. In spite of some successful guidelines, formulation of protein drugs in DDS requires step-by step strategy and methods differing from those used for classical pharmaceutical drugs since proteins are the most delicate ones in term of retaining their biological function. A model protein drug cystatin was selected in our work, having high potential for inactivating cysteine proteases, enzymes involved in processes of tumour invasion and metastasis. Nanoparticles was used as carrier system with the aim to increase the bioavailability of the protein drug by protecting it from premature degradation in biological environment and faciliting its intracellular delivery. Cystatin was incorporated in poly(lactide-co-glycolide) (PLGA) nanoparticles by the water-in-oil-in-water emulsion solvent diffusion method. To preserve its biological activity an optimized technique was developed, adjusting physical and chemical parameters of processes during nanoparticle production. Cystatin-loaded NPs had size of 300-350 nm diameter, and contained 1.6 % (w/w) of cystatin, retaining 85% of its starting activity. To follow cellular uptake of nanoparticles, cystatin was labelled with fluorescent dye (Alexa Fluor 488) prior to its encapsulation into NPs. Image analysis showed rapid internalization of NPs into MCF-10A neoT cells as the fluorescence spots were detected after treatment with NPs. On the other hand, labelled free cystatin was internalised very slowly, suggesting that NPs facilitate the delivery of its cargo into the cells. Cystatin, delivered by NPs, also exerted its inhibitory activity on intracellular target cathepsin B, suggesting that its integrity was preserved throughout the processes of formulation and delivery. On the other hand, free cystatin did not impart proteolityic activity of cathepsin B, when tested under the same conditions using the substate, specific for intracellular cathepsin B. Our results show that protein drug can be formulated in the active form into PLGA NPs, when suitably selecting the process parameters of NP-production. NPs are also able to facilitate delivery of protein drug into the cells, enabling its activity on the intracellular target
关 键 词: 纳米技术; 纳米载体; 药物制剂
课程来源: 视频讲座网
最后编审: 2020-06-08:吴雨秋(课程编辑志愿者)
阅读次数: 49